Jeff Davies

Dr. Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.

As Executive Vice President & General Manager at CSL for the Asia-Pacific region Dr. Davies had overall P&L responsibility for the commercial and operational aspects of the business and oversaw the pharmaceutical, plasma, vaccine, and diagnostic businesses in Australia, New Zealand, China, and the broader Asia-Pacific region.

As the Global Head of CSL-Behring’s Plasma Product Research and Development portfolios, Dr. Davies oversaw and played an important role in the development of leading products, including the multi-billion-dollar Privigen® immunoglobulin product. Dr. Davies was part of CSL’s due diligence teams, which led to the acquisitions of the Plasma Fractionation businesses of Swiss Red Cross (2000) and Aventis Behring (2003) thus transforming CSL into a global company.

Dr. Davies is a partner and founding director of the pharmaceutical consulting firm, Centre for Biopharmaceutical Excellence. Dr Davies has held a number of senior industry board and advisory roles, including representation on the Pharmaceutical Industry Council, the Australian Red Cross Advisory Board and Medicines Australia.

Dr. Davies holds a PhD in Biochemistry from Monash University and is a Graduate of the London Business School’s Senior Executive Program.